keyword
MENU ▼
Read by QxMD icon Read
search

late-stage PCa treatment options

keyword
https://www.readbyqxmd.com/read/27826989/androgen-deprivation-therapy-with-leuprolide-acetate-for-treatment-of-advanced-prostate-cancer
#1
M Raschid Hoda, Mario W Kramer, Axel S Merseburger, Marcus V Cronauer
Hormone sensitive advanced prostate cancer (PCa) is an incurable disease that is treated with a variety of hormonal therapies targeting the androgen/androgen receptor signaling axis. For decades androgen deprivation therapy (ADT) by surgical or chemical castration is the gold standard for the treatment of advanced PCa. Areas covered: This review discusses the pharmacological features of Leuprolide, a luteinizing hormone-releasing hormone (LHRH) agonists/analog and the most commonly used drug in ADT. Expert opinion: Although Leuprolide has been on the market for more than 30 years it is still the leading option for ADT and serves as a basis for most multimodal therapy concepts...
November 9, 2016: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/25564157/the-role-of-stereotactic-body-radiation-therapy-for-pancreatic-cancer-a-single-institution-experience
#2
Shalini Moningi, Avani S Dholakia, Siva P Raman, Amanda Blackford, John L Cameron, Dung T Le, Ana M C De Jesus-Acosta, Amy Hacker-Prietz, Lauren M Rosati, Ryan K Assadi, Shirl Dipasquale, Timothy M Pawlik, Lei Zheng, Matthew J Weiss, Daniel A Laheru, Christopher L Wolfgang, Joseph M Herman
BACKGROUND: Stereotactic body radiation therapy (SBRT) is a promising option for patients with pancreatic cancer (PCA); however, limited data support its efficacy. This study reviews our institutional experience of SBRT in the treatment of locally advanced (LAPC) and borderline resectable (BRPC) PCA. METHODS: Charts of all PCA patients receiving SBRT at our institution from 2010 to 2014 were reviewed. Most patients received pre-SBRT chemotherapy. Primary endpoints included overall survival (OS) and local progression-free survival (LPFS)...
July 2015: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/24864434/-nonarteritic-ischemic-optic-neuropathy-animal-model-and-its-treatment-applications
#3
REVIEW
Hideki Chuman
Nonarteritic ischemic optic neuropathy (NAION) is one of the most common acute unilaterally onset optic nerve diseases. One management problem in terms of NAION is the difficulty of differential diagnosis between NAION and anterior optic neuritis (ON). A second problem is that there is no established treatment for the acute stage of NAION. A third problem is that there is no preventive treatment for a subsequent attack on the fellow eye, estimated to occur in 15 to 25% of patients with NAION. For differentiation of acute NAION from anterior optic neuritis, we investigated the usefulness of laser speckle flowgraphy (LSFG)...
April 2014: Nippon Ganka Gakkai Zasshi
https://www.readbyqxmd.com/read/21430379/castration-resistant-prostate-cancer-targeted-therapies
#4
REVIEW
S Leo, C Accettura, V Lorusso
BACKGROUND: Castration-resistant prostate cancer (CRPC) refers to patients who no longer respond to surgical or medical castration. Standard treatment options are limited. OBJECTIVE: To review the concepts and rationale behind targeted agents currently in late-stage clinical testing for patients with CRPC. METHODS: Novel targeted therapies in clinical trials were identified from registries. The Medline database was searched for all relevant reports published from 1996 to October 2009...
2011: Chemotherapy
https://www.readbyqxmd.com/read/19560857/castration-resistant-prostate-cancer-from-new-pathophysiology-to-new-treatment-targets
#5
REVIEW
Kim N Chi, Anders Bjartell, David Dearnaley, Fred Saad, Fritz H Schröder, Cora Sternberg, Bertrand Tombal, Tapio Visakorpi
CONTEXT: Castration-resistant prostate cancer (CRPC) refers to patients who no longer respond to surgical or medical castration. Standard treatment options are limited. OBJECTIVE: To review the concepts and rationale behind targeted agents currently in late-stage clinical testing for patients with CRPC. EVIDENCE ACQUISITION: Novel targeted therapies in clinical trials were identified from registries. The MEDLINE database was searched for all relevant reports published from 1996 to October 2009...
October 2009: European Urology
https://www.readbyqxmd.com/read/17916461/clinical-proteomics-discovery-of-cancer-biomarkers-using-mass-spectrometry-and-bioinformatics-approaches-a-prostate-cancer-perspective
#6
REVIEW
Balwir Matharoo-Ball, Graham Ball, Robert Rees
Prostate cancer (PCa) is an intractable disease, where diagnosis and clinical prediction of the disease course and response to treatment is compromised by the lack of objective and robust biomarker assays. In late stage metastatic disease, treatment options are limited, although it is recognized that some patients may benefit from immunotherapy and in particular vaccine therapy. However, research into biomarkers that correlate with the clinical outcome of immunotherapy has lagged behind vaccine development...
September 27, 2007: Vaccine
1
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"